Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multi-food Allergy Clear all
Terminated Phase 3 Interventional Results available

Long-term Extension Study of Ligelizumab in Food Allergy

NCT05678959
View directory record Official record
Conditions
Food Allergy
Interventions
Ligelizumab 120 mg, Ligelizumab 240 mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 57 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Head-to-Head Comparison Study Between Different FDA Registered Allergy Skin Test Applicators

NCT07400718
View directory record Official record
Conditions
Allergy, Hypersensitivity, Immediate, Ig-E Mediated Food
Interventions
AllerTest-10 Multi-Head Skin Test Device, Skintestor OMNI Multi-Head Skin Test Device, Multi-Test II Multi-Head Skin Test Device, AllerTest-8 Multi-Head Skin Test Device
Device
Lead sponsor
QHSLab, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Multi Immunotherapy to Test Tolerance and Xolair

NCT02626611
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Buildup
Drug
Lead sponsor
Kari Christine Nadeau
Other
Eligibility
4 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 2 Interventional

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

NCT05432388
View directory record Official record
Conditions
Allergy, Peanut
Interventions
remibrutinib, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Jun 10, 2026, 1:40 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History and Genetics of Food Allergy and Related Conditions

NCT02504853
View directory record Official record
Conditions
Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

NCT02643862
View directory record Official record
Conditions
Food Allergy
Interventions
Xolair, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

NCT01510626
View directory record Official record
Conditions
Immune System Diseases
Interventions
Food proteins, Omalizumab
Dietary Supplement · Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Not applicable Interventional

Treatment of Autistic Children Using NAET Procedures

NCT00277407
View directory record Official record
Conditions
Autism, Food Allergies
Interventions
NAET with acupressure and/or chiropractic procedures
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
3 Years to 10 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated May 6, 2007 · Synced Jun 10, 2026, 1:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy

NCT07287033
View directory record Official record
Conditions
Peanut Allergies
Interventions
MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
Drug
Lead sponsor
Mabylon AG
Industry
Eligibility
12 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Colorado Springs, Colorado • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 1:40 PM EDT
Completed No phase listed Observational

A Study to Monitor the Use of an Amino Acid-Based Infant Formula

NCT02953223
View directory record Official record
Conditions
Cow's Milk Protein Allergy, Eosinophilic Gastrointestinal Disorders, Malabsorption/Maldigestion, Short Bowel Syndrome, Multiple Food Allergies
Interventions
Free amino acid infant formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
1 Day to 12 Months
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Lakeside, Arizona • Phoenix, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07336940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294 Capsule
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Fremont, California • Louisville, Kentucky • College Station, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jun 10, 2026, 1:40 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

NCT07540910
View directory record Official record
Conditions
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions
EDP-978, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)

NCT03679676
View directory record Official record
Conditions
Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions
Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876 suspension, Placebo suspension, TBAJ-876 100 mg tablet, TBAJ-876 25 mg tablet
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 50 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Not applicable Interventional Results available

Safe Administration of Flu Vaccine to Egg Allergic Children

NCT01264601
View directory record Official record
Conditions
Egg Allergy
Interventions
Trivalent Influenza Vaccine
Biological
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
San Diego, California • Ann Arbor, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

HAL-MPE1 Safety and Tolerability Study

NCT02991885
View directory record Official record
Conditions
Peanut Allergy
Interventions
HAL-MPE1, HAL-MPE1 placebo
Biological · Drug
Lead sponsor
HAL Allergy
Industry
Eligibility
5 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Introduction and Maintenance of Still Eating Protein Blends in Support of Infant Nutritional Goals

NCT03667118
View directory record Official record
Conditions
Food Allergy
Interventions
Food Supplement
Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
5 Months to 11 Months
Enrollment
705 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 2 Interventional Results available

Multi OIT to Test Immune Markers After Minimum Maintenance Dose

NCT03181009
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Allergens
Drug
Lead sponsor
Andrew Long, PharmD
Other
Eligibility
2 Years to 25 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Mountain View, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jun 10, 2026, 1:40 PM EDT
Active, not recruiting Phase 4 Interventional

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

NCT06437171
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab
Biological
Lead sponsor
AAADRS Clinical Research Center
Other
Eligibility
6 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jun 10, 2026, 1:40 PM EDT
Recruiting Not applicable Interventional

IBS Skin Patch Test Food Allergy Study

NCT06288672
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
True avoidance diet, Sham avoidance diet
Other
Lead sponsor
IBS-80, LLC
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
North Wales, Pennsylvania • Barboursville, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT04271514
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug
Lead sponsor
RAPT Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Jun 10, 2026, 1:40 PM EDT
Not listed Phase 2 Interventional

E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy

NCT02879006
View directory record Official record
Conditions
Food Allergy
Interventions
Chinese Herbal Medication, Placebo, Omalizumab, Multi OIT
Drug
Lead sponsor
Xiu-Min Li
Other
Eligibility
6 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Jun 10, 2026, 1:40 PM EDT
Completed Phase 1 Interventional

Single Center Food Allergy Oral Immunotherapy Study

NCT01490177
View directory record Official record
Conditions
Immune System Diseases
Interventions
Food proteins
Drug
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Jun 10, 2026, 1:40 PM EDT